Arcutis Biotherapeutics (ARQT) closed at $27.39 on November 10, 2026, up 4.5% from the previous close, on volume of 2,035,125 shares (30-day average 2,402,843).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Calendar Call Spread | 16-Oct : 20-Nov-26 27.5 C | 3,902 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 6-Nov 4:00 PM ET)
Arcutis Advances Phase 3 Atopic Dermatitis Study as Investors Await Results
TipRanks (Fri, 6-Nov 11:32 AM ET)
Market Chameleon (Thu, 5-Nov 3:18 AM ET)
Globe Newswire (Thu, 5-Nov 8:00 AM ET)
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Wed, 4-Nov 4:00 PM ET)
Arcutis Appoints Rob Scott, MD to Board of Directors
Globe Newswire (Wed, 28-Oct 9:00 AM ET)
Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Globe Newswire (Tue, 27-Oct 4:00 PM ET)
Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
Globe Newswire (Wed, 21-Oct 4:00 PM ET)
Globe Newswire (Fri, 9-Oct 8:00 AM ET)
Arcutis' ZORYVE (roflumilast) Wins 2026 Marie Claire Beauty Award
Globe Newswire (Tue, 6-Oct 8:19 AM ET)
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Arcutis Biotherapeutics trades on the NASDAQ stock market under the symbol ARQT.
As of November 11, 2026, ARQT stock price climbed to $28.08 with 1,149,985 million shares trading.
ARQT has a beta of 0.78, meaning it tends to be less sensitive to market movements. ARQT has a correlation of 0.04 to the broad based SPY ETF.
ARQT has a market cap of $3.53 billion. This is considered a Mid Cap stock.
Last quarter Arcutis Biotherapeutics reported $144 million in Revenue and $.06 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.11.
In the last 3 years, ARQT traded as high as $34.80 and as low as $1.76.
The top ETF exchange traded funds that ARQT belongs to (by Net Assets): IJR, VTI, XBI, IWM, VXF.
ARQT has outperformed the market in the last year with a return of +18.2%, while the SPY ETF gained +12.7%. In the last 3 month period, ARQT beat the market returning +8.3%, while SPY returned -1.4%. However, in the most recent 2 weeks ARQT has underperformed the stock market by returning -11.4%, while SPY returned -1.2%.
ARQT support price is $26.39 and resistance is $28.38 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARQT shares will trade within this expected range on the day.
